Stockreport

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Conve...

Allogene Therapeutics, Inc.  (ALLO) 
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report
PDF Proprietary Dagger ® Technology Enables ALLO-329 to Overcome Rejection and Expand the Presence of Alloreactive T Cells Presented Data Demonstrates that ALLO-329 Could [Read more]